‘This terrible disease’: Ovarian cancer is deadly, but new tests, treatments start to emerge

May 18, 2019 5:00 pm

By Sarah Elizabeth Richards

Photo: Liz Laats with husband Andy Laats and their three children. She died three years ago of ovarian cancer. The San Diego resident had suffered through 88 rounds of chemotherapy during 10 treatment regimens over six Read more

Study Identifies How Cancer Drug Inhibits DNA Repair in Cancer Cells

May 15, 2019 6:00 pm

According to researchers at Yale Cancer Center, a cancer drug thought to be of limited use possesses a superpower of sorts: It is able to stop certain cancer cells from repairing their DNA in order to survive. The study, published … Read more

Research Could Lead to More Precise Diagnosis and Treatment of Ovarian Cancer

May 8, 2019 5:00 pm

By Michael Brown

Oncologists may soon have an accurate and inexpensive way of differentiating between types of ovarian cancer that will improve how patients are treated, thanks to findings from a national research study co-led out of the University of … Read more

Epithelial Ovarian Cancer: BRCA Mutations, Brain Mets, and Breastfeeding

May 6, 2019 5:00 pm

By Kristin Jenkins

The presence of a BRCA germ line mutation in patients with invasive epithelial ovarian cancer may confer a short-term survival advantage, but is not associated with a reduction in long-term mortality, researchers found.

A follow-up study comparing … Read more

Liquid Biopsies Can Point to Best Ovarian Cancer Treatment

May 6, 2019 4:00 pm

DNA shed by tumors into the bloodstream is starting to be used for the early detection of cancer and for monitoring how well treatment is working. Such DNA, which is called circulating tumor DNA (ctDNA), hasn’t been quite as helpful

Read more

Study Shows Ovarian Cancer Survival Increase

May 3, 2019 5:00 pm

A gynecologic oncologist at the Stephenson Cancer Center at OU Medicine was a national leader of a newly published research study that reveals good news for women with ovarian cancer—longer survival times plus a treatment option that causes fewer difficult … Read more

Managing Chemotherapy Side Effects for Ovarian Cancer

May 1, 2019 5:15 pm

By Dr. Leslie Boyd

Ovarian cancer produces the type of tumor that oncologists like to call “chemo-sensitive”—which is pretty good news for anyone diagnosed. Ovarian cancer cells have been shown to respond well to a combination of chemo drugs, which … Read more

Changes in the Metabolism of Normal Cells Promotes the Metastasis of Ovarian Cancer Cells

May 1, 2019 5:00 pm

A systematic examination of the tumor and the tissue surrounding it—particularly normal cells in that tissue, called fibroblasts—has revealed a new treatment target that could potentially prevent the rapid dissemination and poor prognosis associated with high-grade serous carcinoma (HGSC), a … Read more

6 Questions to Ask Your Doctor After an Ovarian Cancer Diagnosis

April 30, 2019 5:00 pm

Two of the key points this article touches on refer to finding a clinical trial and seeking mental health support. At Clearity, we can help! Check out our Clinical Trial Finder, as well as Steps Through OC, a Read more

Impact of Somatic Molecular Profiling on Clinical Trial Outcomes in Rare Epithelial Gynecologic Cancer Patients

April 25, 2019 6:00 pm

Given that the limited number of patients and differences in biologic behavior pose challenges in conducting clinical trials in rare malignancies, researchers determined whether using genomic profiling for rare gynecologic malignancies is feasible and have clinical utility. They analyzed somatic

Read more

Still No Benefit of IP Chemo for Ovarian Cancer

April 24, 2019 5:00 pm

By Charles Bankhead

No PFS or OS benefit, more toxicity with IP verses IV regimens

Final results of a highly anticipated randomized trial failed to show a survival benefit with intraperitoneal (IP) chemotherapy in patients with newly diagnosed advanced ovarian … Read more

Imaging System Helps Surgeons Remove Tiny Ovarian Tumors

April 23, 2019 5:00 pm

By Anne Trafton

More effective surgery could boost survival rates for ovarian cancer.

Ovarian cancer is usually diagnosed only after it has reached an advanced stage, with many tumors spread throughout the abdomen. Most patients undergo surgery to remove as

Read more

Niraparib Offers New Option in Heavily Pretreated Ovarian Cancer

April 17, 2019 7:00 pm

By Dave Levitan

Niraparib showed promising and clinically relevant activity as therapy for heavily pretreated patients with ovarian cancer, according to a new phase II study. This was particularly true among women with homologous recombination deficiency (HRD)-positive tumors.

“Although most … Read more

Types of Drugs Used to Treat Cancer

April 15, 2019 7:00 pm

By Andrea S. Blevins Primeau, PhD, MBA

There are many different types of agents used in the treatment of cancer, and they can generally be classified according to molecule type or their basic mechanism of action. Different cancer types have … Read more

Ovarian Cancer Patients Undertested for Mutations that Could Guide Clinical Care

April 9, 2019 4:00 pm

By Krista Conger

A large study of women with breast and ovarian cancer has revealed significant gaps between national guidelines for genetic testing and actual testing practices, according to researchers from Stanford and five other institutions.

Fewer than a quarter … Read more

Initial Phase 2 Data From an IMV Clinical Study Continues to Demonstrate DPX-Survivac’s Prior Trend as a Potential Monotherapy Treatment for Advanced Ovarian Cancer

March 26, 2019 5:00 pm

IMV Inc., a clinical stage immuno-oncology corporation, today announced preliminary data from the phase 2 cohort of the DECIDE clinical study. Six patients receiving DPX-Survivac monotherapy with intermittent low-dose cyclophosphamide (mCPA) have reached the first CT scan assessment with key … Read more

SGO 2019: Maintenance Rucaparib Effective for All Age Groups in Ovarian Cancer

March 22, 2019 5:00 pm

By Christina Bennett, MS

Rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, was effective as a maintenance therapy across all age groups of patients with recurrent ovarian cancer, according to the results of a post-hoc exploratory analysis of ARIEL3 presented at … Read more

‘End of the Road’ for Trabectedin in Ovarian Cancer?

March 21, 2019 7:00 pm

By Ian Ingram

Trial stopped for futility, but 13-month OS improvement seen in patients with BRCA mutations.

Trabectedin (Yondelis) plus pegylated liposomal doxorubicin (PLD) failed to improve survival in a phase III trial of third-line ovarian cancer, but a survival … Read more

Patients Need Access to More Information About the Cost of Cancer Care

March 21, 2019 5:00 pm

By Brielle Benyon

Financial distress puts a major burden on patients with cancer and their families. And while there are numerous resources that clinicians can share with their patients to help with co-pays and other money-related issues, they are not … Read more

Avelumab Combo Falls Short in Advanced Ovarian Cancer

March 20, 2019 7:00 pm

By Ian Ingram

But showed promise in PD-L1-positive group.

Adding avelumab (Bavencio) to pegylated liposomal doxorubicin (PLD) failed to improve survival outcomes for patients with platinum-resistant or refractory ovarian cancer in a phase III trial reported here.

In the intent-to-treat … Read more